ONCOS-102 (AdV5/3-Δ24-GM-CSF), which is a serotype 5 adenovirus, with a chimeric capsid for enhanced gene delivery and a 24 bp deletion in the Rb binding site of the E1A region to restrict cancer cell replication and engineered GM-CSF expression for an enhanced immunostimulatory effect, is another adenovirus that has been studied in clinical trials. Here, CSF2 is linked to cancer.